Skip to main content
. 2019 Sep 19;4(18):e128568. doi: 10.1172/jci.insight.128568

Figure 4. Vigabatrin attenuates chondrocyte hypertrophy and protects against injury-induced OA progression.

Figure 4

(A) Mitochondrial respiration was measured in primary articular chondrocytes treated with PBS or vigabatrin (n = 8). (B) Real-time qPCR analyses of gene expression from articular chondrocytes pretreated with PBS and vigabatrin (100 μM) following IL-1β treatment (n = 3). (C) Representative images of histological sections of PBS-treated and vigabatrin-treated (200 mg/kg) knee joints at 6 and 10 weeks following MLI surgery (n = 5). (D) BV/TV ratios of tibial subchondral bone were calculated from the micro-CT images (n = 7). Quantification of histological assessment by OARSI scoring (E) and cartilage area (F) (n = 7). (G) Immunohistochemical analyses for Prg4, Mmp13, and Col10A1 on knee sections of PBS- and vigabatrin-treated cartilage 10 weeks after MLI. *P < 0.05 by 2-tailed Student’s t test (A and D) and ANOVA with post hoc test (B, E, and F). Scale bars: 50 μm.